Biogen, Eisai Alzheimer’s drug review delayed in EU
Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.
European markets extend gains as traders digest economic data, earnings
AM to reflect current markets movement.  London (UKX) +0.34%. Germany (DAX:IND) +0.27% Germany's unemployment rate rises to 6.2% in January France (CAC:IND) +0.52% Annual inflation rate in France ...
Honda and Nissan are expected to announce merger plans within a few weeks
Honda Motor Co. (NYSE:HMC) and Nissan Motor Co. (NSNAY) intend to unveil a detailed outline of their business integration ...